Posted by Michael Wonder on 22 Jul 2019
Novartis key multiple sclerosis product Gilenya approved in China
19 July 2019 - Chinese National Medical Products Administration (NMPA) approved Gilenya for relapsing forms of multiple sclerosis for adults and children 10 years and older.
Novartis is committed to bringing innovation to China and to reimagining care for patients.
Entresto was approved in 2017. Following the approval of Cosentyx in March, Gilenya is the next key Novartis product approved from the list of urgently needed drugs in China.
